The transition to magic bullets-transition state analogue drug design

Gary B. Evans, Vern L. Schramm, Peter C. Tyler

Research output: Contribution to journalReview article

Abstract

In the absence of industry partnerships, most academic groups lack the infrastructure to rationally design and build drugs via methods used in industry. Instead, academia needs to work smarter using mechanism-based design. Working smarter can mean the development of new drug discovery paradigms and then demonstrating their utility and reproducibility to industry. The collaboration between Vern Schramm's group at the Albert Einstein College of Medicine, USA and Peter Tyler at the Ferrier Research Institute at The Victoria University of Wellington, NZ has refined a drug discovery process called transition state analogue design. This process has been applied to several biomedically relevant nucleoside processing enzymes. In 2017, Mundesine®, conceived using transition state analogue design, received market approval for the treatment of peripheral T-cell lymphoma in Japan. This short review looks at a brief history of transition state analogue design, the fundamentals behind the development of this process, and the success of enzyme inhibitors produced using this drug design methodology.

Original languageEnglish (US)
Pages (from-to)1983-1993
Number of pages11
JournalMedChemComm
Volume9
Issue number12
DOIs
StatePublished - Jan 1 2018

Fingerprint

Magic
Drug Design
Industry
Drug Discovery
Pharmaceutical Preparations
Peripheral T-Cell Lymphoma
Victoria
Enzyme Inhibitors
Nucleosides
Japan
Medicine
T-cells
Enzymes
Therapeutics
Processing

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Pharmacology
  • Pharmaceutical Science
  • Drug Discovery
  • Organic Chemistry

Cite this

The transition to magic bullets-transition state analogue drug design. / Evans, Gary B.; Schramm, Vern L.; Tyler, Peter C.

In: MedChemComm, Vol. 9, No. 12, 01.01.2018, p. 1983-1993.

Research output: Contribution to journalReview article

Evans, Gary B. ; Schramm, Vern L. ; Tyler, Peter C. / The transition to magic bullets-transition state analogue drug design. In: MedChemComm. 2018 ; Vol. 9, No. 12. pp. 1983-1993.
@article{319e8325e36040c39028bc3fe2dce757,
title = "The transition to magic bullets-transition state analogue drug design",
abstract = "In the absence of industry partnerships, most academic groups lack the infrastructure to rationally design and build drugs via methods used in industry. Instead, academia needs to work smarter using mechanism-based design. Working smarter can mean the development of new drug discovery paradigms and then demonstrating their utility and reproducibility to industry. The collaboration between Vern Schramm's group at the Albert Einstein College of Medicine, USA and Peter Tyler at the Ferrier Research Institute at The Victoria University of Wellington, NZ has refined a drug discovery process called transition state analogue design. This process has been applied to several biomedically relevant nucleoside processing enzymes. In 2017, Mundesine{\circledR}, conceived using transition state analogue design, received market approval for the treatment of peripheral T-cell lymphoma in Japan. This short review looks at a brief history of transition state analogue design, the fundamentals behind the development of this process, and the success of enzyme inhibitors produced using this drug design methodology.",
author = "Evans, {Gary B.} and Schramm, {Vern L.} and Tyler, {Peter C.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1039/c8md00372f",
language = "English (US)",
volume = "9",
pages = "1983--1993",
journal = "MedChemComm",
issn = "2040-2503",
publisher = "Royal Society of Chemistry",
number = "12",

}

TY - JOUR

T1 - The transition to magic bullets-transition state analogue drug design

AU - Evans, Gary B.

AU - Schramm, Vern L.

AU - Tyler, Peter C.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - In the absence of industry partnerships, most academic groups lack the infrastructure to rationally design and build drugs via methods used in industry. Instead, academia needs to work smarter using mechanism-based design. Working smarter can mean the development of new drug discovery paradigms and then demonstrating their utility and reproducibility to industry. The collaboration between Vern Schramm's group at the Albert Einstein College of Medicine, USA and Peter Tyler at the Ferrier Research Institute at The Victoria University of Wellington, NZ has refined a drug discovery process called transition state analogue design. This process has been applied to several biomedically relevant nucleoside processing enzymes. In 2017, Mundesine®, conceived using transition state analogue design, received market approval for the treatment of peripheral T-cell lymphoma in Japan. This short review looks at a brief history of transition state analogue design, the fundamentals behind the development of this process, and the success of enzyme inhibitors produced using this drug design methodology.

AB - In the absence of industry partnerships, most academic groups lack the infrastructure to rationally design and build drugs via methods used in industry. Instead, academia needs to work smarter using mechanism-based design. Working smarter can mean the development of new drug discovery paradigms and then demonstrating their utility and reproducibility to industry. The collaboration between Vern Schramm's group at the Albert Einstein College of Medicine, USA and Peter Tyler at the Ferrier Research Institute at The Victoria University of Wellington, NZ has refined a drug discovery process called transition state analogue design. This process has been applied to several biomedically relevant nucleoside processing enzymes. In 2017, Mundesine®, conceived using transition state analogue design, received market approval for the treatment of peripheral T-cell lymphoma in Japan. This short review looks at a brief history of transition state analogue design, the fundamentals behind the development of this process, and the success of enzyme inhibitors produced using this drug design methodology.

UR - http://www.scopus.com/inward/record.url?scp=85058627193&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058627193&partnerID=8YFLogxK

U2 - 10.1039/c8md00372f

DO - 10.1039/c8md00372f

M3 - Review article

AN - SCOPUS:85058627193

VL - 9

SP - 1983

EP - 1993

JO - MedChemComm

JF - MedChemComm

SN - 2040-2503

IS - 12

ER -